

2015

Reply to: Nasal endoscopy to characterize sinonasal disease

A. E. Dixon

M. Castro

R. I. Cohen

Zucker School of Medicine at Hofstra/Northwell

L. B. Gerald

J. T. Holbrook

*See next page for additional authors*Follow this and additional works at: <https://academicworks.medicine.hofstra.edu/articles>Part of the [Internal Medicine Commons](#)

Recommended Citation

Dixon A, Castro M, Cohen R, Gerald L, Holbrook J, Irvin C, Mohapatra S, Peters S, Rayapudi S, Wise R, . Reply to: Nasal endoscopy to characterize sinonasal disease. . 2015 Jan 01; 136(1):Article 2092 [p.]. Available from: <https://academicworks.medicine.hofstra.edu/articles/2092>. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.

Authors

A. E. Dixon, M. Castro, R. I. Cohen, L. B. Gerald, J. T. Holbrook, C. G. Irvin, S. Mohapatra, S. P. Peters, S. Rayapudi, R. A. Wise, and +1 additional author



HHS Public Access

Author manuscript

J Allergy Clin Immunol. Author manuscript; available in PMC 2017 September 20.

Published in final edited form as:

J Allergy Clin Immunol. 2015 July ; 136(1): 212–213. doi:10.1016/j.jaci.2015.04.003.

Reply

Anne E. Dixon, MA, BM, BCh^a, Mario Castro, MD, MPH^b, Rubin I. Cohen, MD^c, Lynn B. Gerald, PhD, MPH^d, Janet T. Holbrook, PhD^e, Charles G. Irvin, PhD^a, Shyam Mohapatra, PhD^f, Stephen P. Peters, MD^g, Sobharani Rayapudi, MD^h, Elizabeth A. Sugar, PhDⁱ, Robert A. Wise, MD^h, and for the American Lung Association–Asthma Clinical Research Centers

^aDepartment of Medicine, University of Vermont, Burlington, Vt

^bDepartment of Medicine, Washington University School of Medicine, St Louis, Mo

^cThe Thalheim Asthma Center Hofstra, North Shore-Long Island Jewish School of Medicine, New Hyde Park, NY

^dArizona Respiratory Center, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Ariz

^eDepartment of Epidemiology, Johns Hopkins University, Baltimore, Md

^fDepartment of Medicine, University of South Florida, Tampa, Fla

^gSection on Pulmonary, Critical Care, Allergy & Immunologic Diseases, Wake Forest University, Winston-Salem, NC

^hDepartment of Medicine, Johns Hopkins University, Baltimore, Md

ⁱDepartment of Biostatistics, Johns Hopkins University, Baltimore, Md

To the Editor

We agree with Dr Lipworth¹ that our study does not address whether treating complex sinonasal disease documented by endoscopy would affect asthma outcomes. This was not the purpose of our study. The purpose of our study was to determine whether treating

Disclosure of potential conflict of interest: A. E. Dixon's institution has received funding from the National Institutes of Health and Merck; she has received consultancy fees from Roche and has received grants or has grants pending from Pfizer and receives royalties from Springer. M. Castro's institution has received funding from the National Institutes of Health (NIH) and has received grants or has grants pending from Boston Scientific, Amgen, Ception, Cephalon, Teva, Genentech, Medimmune, Merck, Novartis, GlaxoSmithKline, Sanofi Aventis, Vectura, Next Bio, and KalosBios; he has received consultancy fees from Asthmatx/Boston Scientific, Genentech, IPS/Holaira, and Neostem; has received payment for delivering lectures from GlaxoSmithKline, Genentech, Boston Scientific, Boehringer Ingelheim, and Teva; receives royalties from Elsevier; and has stock/stock options from Sparo. R. I. Cohen's institution has received funding from the American Lung Association–Asthma Clinical Research Center. C. G. Irvin has received consultancy fees from TEVA and has received grants or has grants pending from Hydra Bioscience and receives royalties from UpToDate. S. P. Peters has received consultancy fees from the Coordination Center at Johns Hopkins, AstraZeneca, Aerocrine, Airsonett AB, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Ono Pharmaceuticals, Pfizer, Sunovion, Targacept, TEVA, Pharmaceutical Product Development, LLC, and Quintiles; has received payment for delivering lectures from Integrity CE; and receives royalties from UpToDate. R. A. Wise's institution has received funding from Merck, as well as consultancy fees from AstraZeneca, Merck, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Pfizer, Mylan, Roche, Janssen, Pulmonx, Spiration, Intermune, Medimmune, Sunovion, and Forest; he has received support for travel and other meeting-related expenses from Forest. The rest of the authors declare that they have no conflicts of interest.

chronic sinonasal disease in a diverse patient population in a manner analogous to that widely practiced in non-tertiary care specialty practices would improve asthma control.²

Sinonasal disease was determined by using a validated questionnaire with high sensitivity and specificity for determining the presence of sinonasal disease, which was superior to endoscopy and computed tomographic imaging.³ The reason for using a questionnaire rather than invasive testing to document disease was to mirror common clinical practice.

Research personnel were trained in drug administration, and these personnel instructed all participants in use of the study drug. Sinus symptoms improved significantly in adults, suggesting efficacy of the dose of medication used in this population. Our findings are entirely consistent with those of other multicenter studies of nasal steroids in the treatment of asthma.^{4,5}

Our overall goal was to study the treatment of sinonasal disease in a diverse patient population with poorly controlled asthma to maximize the generalizability of the results to clinical practice rather than to test the unified airway disease hypothesis in a highly select group of patients.

Acknowledgments

Supported by grants from the National Heart Blood and Lung Institute (U01HL089464, U01 HL089510, and UL1 TR000448) and the American Lung Association. Study drug and placebo were provided by Merck (Whitehouse Station, NJ).

References

1. Lipworth B. Nasal endoscopy to characterize sinonasal disease. *J Allergy Clin Immunol.* 2015; 136:212.
2. Dixon AE, Castro M, Cohen RI, Gerald LB, Holbrook JT, Irvin CG, et al. American Lung Association–Asthma Clinical Research Centers’ Writing Committee. Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma. *J Allergy Clin Immunol.* 2015; 135:701-9.e5. [PubMed: 25174863]
3. Dixon AE, Sugar EA, Zinreich SJ, Slavin RG, Corren J, Naclerio RM, et al. Criteria to screen for chronic sinonasal disease. *Chest.* 2009; 136:1324–32. [PubMed: 19581356]
4. Katial RK, Oppenheimer JJ, Ostrom NK, Mosnaim GS, Yancey SW, Waitkus-Edwards KR, et al. Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. *Allergy Asthma Proc.* 2010; 31:68–75. [PubMed: 20167147]
5. Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E, et al. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. *Chest.* 2005; 128:1910–20. [PubMed: 16236835]